Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Incidence of DLT [ Time Frame: First 28 days of dosing ]
Objective response rate (ORR) as per RECIST v1.1 [ Time Frame: Baseline, every 8 weeks until discontinuation for an expected average of 4 months ]
Secondary Outcome Measures :
Incidence of Adverse Events (AEs) and Serious Advers Events (SAEs) [ Time Frame: Continously throughout the study until 30 days after treatment discontinuation ]
Severity of AEs and SAEs and dose reductions and interruptions [ Time Frame: Continously throughout the study until 30 days after treatment discontinuation ]
Duration of response (DOR) [ Time Frame: Baseline, every 8 weeks until discontinuation for an expected average of 4 months ]
per RECIST v1.1
Progression free survival (PFS) [ Time Frame: Baseline, every 8 weeks until discontinuation for an expected average of 4 months ]
per RECIST v1.1
Best overall response (BOR) [ Time Frame: Baseline and every 8 weeks for an expected average of 4 months ]
per RECIST v1.1
Plasma concentration and Pharmacokinetics (PK) parameters of CLR457 [ Time Frame: During phase I: Baseline; Cycle 1 (C1) Day 1 (D1), 2, 8, 15, 16 and 22; Cycle 2 Day 1, 2, from Cycle 3 to cycle 6 on Day 1 During Phase II: Baseline; Cycle 1 Day 1, 2, 8, 15, 16 and 22 ]
Parameters including but not limited to Cmax, Cmin, AUCinf, AUCtlast, AUCtau and T1/2
Changes from baseline in glucose metabolism markers (fasting glucose and insulin) [ Time Frame: For Phase I and II C1D1, C1D2, C1D15, C1D16 and for Phase I only C2D1 and C2D2 ]
Pre- and post- treatment immunohistochemistry of PI3K pathway molecules in newly obtained paired tumor samples [ Time Frame: Baseline, C2D1 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Written informed consent must be obtained prior to any screening procedures
Phase I: Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by modified RECIST version 1.1 who have progressed despite standard therapy or be intolerant of standard therapy, or for whom no standard therapy exists, who have tumors harboring one of the following: confirmed PIK3CA mutation or amplification, PTEN loss of function, EGFR mutation, cMET activation and/or HER2 overexpression. Endometrial carcinoma will not be selected for any molecular status.
Phase II: Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by modified RECIST version 1.1, who progressed despite standard therapy or be intolerant of standard therapy, or for whom no standard therapy exists, fitting in one of the following groups: Group 1: patients with PIK3CA mutated or amplified ER positive (ER+) breast cancer ; Group 2: patients with endometrial carcinoma (not selected for any molecular status); Group 3: patients with solid tumors (with the exception of PIK3CA mutant/amplified ER+ breast cancer and endometrial carcinoma) harboring PIK3CA mutation or amplification/any PTEN status; Group 4: patients with solid tumors (with the exception of endometrial carcinoma) harboring PTEN loss of function/ PIK3CA wild type; Group 5: non-small cell lung cancer harboring cMET activation and/or EGFR mutation. Up to 3 lines of chemotherapy allowed in advanced/metastatic setting.
ECOG Performance Status ≤ 2.
Availability of a representative formalin fixed paraffin embedded tumor tissue sample. If archival tumor sample is not available, a newly obtained tumor sample needs to be submitted instead.
Brain metastasis unless treated and neurologically stable
Patient having out of range laboratory values defined as:
Hepatic and renal function:
Serum total Bilirubin ≥ 1.5 x ULN (upper limit of normal) or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2.5 x ULN
For patients with tumor involvement of the liver AST or ALT > 5 x ULN
For patients with Gilbert's syndrome total bilirubin > 2.5 x ULN
Serum creatinine > 1.5 x ULN and/or measured or calculated creatinine clearance < 75% LLN (lower limit of normal)
Bone marrow function:
Platelets < 100 x 109/L
Hemoglobin (Hgb) < 9 g/dL
Absolute Neutrophil Count (ANC) < 1.5 x 109/L
Clinically significant and/or uncontrolled heart disease such as congestive heart failure (CHF) requiring treatment (NYH grade ≥2), hypertension or arrhythmia
Left ventricular ejection fraction (LVEF) < 45% as determined by MUGA scan or ECHO
QTcF >480 msec on screening ECG or congenital long QT syndrome
Acute myocardial infarction (AMI) or unstable angina pectoris < 3 months prior to study entry
Peripheral neuropathy CTCAE Grade ≥2
History of pancreatitis of any grade
Patients with diabetes mellitus requiring insulin treatment and/or with clinical signs or with Fasting Plasma Glucose (FPG) ≥ 140 mg/dL / 7.8 mmol/L
Patients receiving treatment with medications that are known to be 1) strong inhibitors or inducers of CYP3A4/5; 2) CYP2C9 substrate with narrow therapeutic index; 3) QT prolonging agents; 4) proton pump inhibitors unless these medications can be discontinued at least a week prior to start of treatment.
Other protocol-defined inclusion/exclusion criteria may apply.